Category Archives: Emerging Markets

Tiered Pricing Not Always a Win-Win

By Ben Comer | Published: November 22, 2011
Tiered pricing, or selling critical medicines to developing countries at a standardized discount price, can improve access in the short term, but arbitrary demographic groupings and misaligned incentives often stack the deck in favor of manufacturers, not patients.
Also posted in Corporate Responsibility, Global, IP, Manufacturing, Market Access, R&D, Strategy, pricing | 2 Comments

European Pharma 1981-2011: Survival of the Fittest?

By Guest Blogger | Published: October 5, 2011
This month sees Pharmaceutical Executive magazine reach its 30th birthday. In line with that milestone, Reflector assesses what the last three decades have meant for European pharma — and shows how the game has changed beyond recognition. Thirty years is a long time in any industry. The coalmining industry, the market for air travel, or telecommunications [...]
Also posted in Europe, Global, Guest Blog, IP, Pharm Exec Magazine, R&D, Regulatory, healthcare, leadership | Tagged , , , , , , | Leave a comment

Planning Beyond the Petri Dish: A Pfizer Case Study

By William Looney | Published: June 29, 2011
Pfizer’s crizotinib development program combined organization, art, and science— and a large dose of unforeseen risk. The path to commercializing a breakthrough discovery is rarely a linear process. The orderly rationale of the scientific method is often overtaken by the random artistry of passion, personality, business culture, and sheer luck. Each plays a [...]
Also posted in Global, R&D | Tagged , , , , , , , | Leave a comment

Indian Government Proposes Ban on Physician Gifts

By Ben Comer | Published: June 6, 2011
India’s Department of Pharmaceuticals released a 14-page “voluntary code” for drug marketers, which includes a strict ban on gifts to prescribers, among other things. The code, which is open for public comment until June 30th, states that “no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to persons qualified to prescribe” [...]
Also posted in Advertising, Global, Marketing, Medical Education, Strategy | Tagged , , , , , , | Leave a comment

Biosimilars Spend to Reach $2.5 Bln by 2015: IMS

By Ben Comer | Published: May 18, 2011
Global spending on biosimilars is expected to reach between $2 and $2.5 billion by 2015, up from $311 million in 2010, according to an IMS forecast. Total spend on biologics is expected to climb as high as $200 billion. On a call with reporters yesterday, Murray Aitken, executive director of the IMS Institute for Healthcare Informatics, [...]
Also posted in Agency Insight, Biotech, Europe, Strategy | Tagged , , | 1 Comment